The minimal clinically important difference of the scleroderma clinical trials consortium damage index
The most appropriate minimal clinically important difference for the Scleroderma Clinical Trials Consortium Damage Index is a change of ⩾ 1.0 units in the Scleroderma Clinical Trials Consortium Damage Index as is already recognized by patients as a significant change after 1 year. This can be applied to group means as well as to individuals where an ordinal change is required.
Authors
- Wendy Stevens
- Mandana Nikpour (ORCID: https://orcid.org/0000-0002-6585-5611)
- Susanna Proudman (ORCID: https://orcid.org/0000-0002-3046-9884)
- Mianbo Wang (ORCID: https://orcid.org/0009-0007-7148-2827)
- Murray Baron (ORCID: https://orcid.org/0000-0002-0435-6165)
- Dylan Hansen (ORCID: https://orcid.org/0000-0001-5777-7476)
Institutions
- The University of Sydney (AU)
- Royal Adelaide Hospital (AU)
- Royal Prince Alfred Hospital (AU)
- Jewish General Hospital (CA)
- St Vincent's Hospital Melbourne (AU)
- Institute for Musculoskeletal Health (AU)
- McGill University (CA)
Publication Details
- Journal
- Journal of Scleroderma and Related Disorders
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1177/23971983251327808
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00